Dynavax Technologies | SCHULD



Debt Veränderung Datum
AbbVie USD 67.14B 3.94B 2024-12
Adma Biologics USD 72.34M 28.99M 2024-12
Amgen USD 60.1B 299M 2024-12
AstraZeneca USD 30.3B 1.27B 2024-12
Biogen USD 6.3B 1.9M 2024-12
BioMarin Pharmaceutical USD 596.24M 1.61M 2024-12
Bristol-Myers Squibb USD 49.71B 62M 2025-03
Dynavax Technologies USD 223.85M 293K 2024-12
Gilead Sciences USD 26.71B 3.46B 2024-12
Glaxosmithkline GBP 16.99B 927M 2024-12
Merck USD 37.11B 1.02B 2024-12
Neurocrine Biosciences USD 0 0 2024-12
Novartis USD 31.26B 828M 2024-12
Pfizer USD 64.35B 3.35B 2024-12
Regeneron Pharmaceuticals USD 2.7B 400K 2024-12
Roche Holding CHF 34.44B 5.23B 2024-06
Sarepta Therapeutics USD 1.14B 90.44M 2024-12
TG Therapeutics USD 244.43M 271K 2024-12
Vertex Pharmaceuticals USD 112.8M 1.2M 2024-12



Dynavax Technologies SCHULD - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Apr 2025.